Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Rapporto sulle azioni

Cap. di mercato: US$438.0m

Arcturus Therapeutics Holdings Crescita futura

Future criteri di controllo 5/6

Arcturus Therapeutics Holdings prevede che gli utili e i ricavi cresceranno rispettivamente di 70.8% e 35.3% all'anno. Si prevede che l'EPS crescerà di 70.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -157.6% in 3 anni.

Informazioni chiave

70.8%

Tasso di crescita degli utili

70.3%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.4%
Tasso di crescita dei ricavi35.3%
Rendimento futuro del capitale proprio-157.6%
Copertura analitica

Good

Ultimo aggiornamento08 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14

Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Oct 04
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 09

Arcturus: A Hidden Gem In The Biotech Sector

Jun 08

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:ARCT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202635149-151N/A8
12/31/2025214-47-192N/A10
12/31/2024175-64N/AN/A10
9/30/2024160-63-62-60N/A
6/30/2024164-72-71-69N/A
3/31/2024125-1071012N/A
12/31/2023167-30-21-18N/A
9/30/202329699137143N/A
6/30/202326480126133N/A
3/31/20232811113945N/A
12/31/202220692432N/A
9/30/202252-147-176-171N/A
6/30/202241-165-150-145N/A
3/31/202215-198-147-141N/A
12/31/202112-204-138-135N/A
9/30/20219-196-102-99N/A
6/30/20219-163-100-98N/A
3/31/20219-119-76-74N/A
12/31/202010-72-45-43N/A
9/30/202010-52-45-44N/A
6/30/202011-38-32-31N/A
3/31/202019-29-14-13N/A
12/31/201921-26-7-6N/A
9/30/201925-16-5-5N/A
6/30/201926-13-9-9N/A
3/31/201918-22-27-26N/A
12/31/201816-22-22-21N/A
9/30/201810-26-11-10N/A
6/30/201810-25N/A-5N/A
3/31/201812-16N/A1N/A
12/31/201713-11N/A0N/A
12/31/201620-2N/A-3N/A
12/31/20156-2N/A8N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ARCT diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che ARCT diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede ARCT diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ARCT ( 35.3% all'anno) crescerà più rapidamente del mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ARCT ( 35.3% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che ARCT non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita